KZR

Kezar Life Sciences, Inc. KZR

KZR
Kezar Life Sciences, Inc. GBIO
Generation Bio Co. ERAS
Erasca, Inc. CCCC
C4 Therapeutics, Inc. EWTX
Edgewise Therapeutics, Inc. SRRK
Scholar Rock Holding Corporation CRNX
Crinetics Pharmaceuticals, Inc. REPL
Replimune Group, Inc. STRO
Sutro Biopharma, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode KZR GBIO ERAS CCCC EWTX SRRK CRNX REPL STRO
6M 5.06 % 61.12 % 95.16 % 76.90 % 31.55 % 9.50 % 52.23 % -39.46 % 35.87 %
YTD -36.83 % -43.83 % -10.37 % -40.07 % -44.42 % -30.57 % -14.03 % -64.57 % -57.59 %
1Y -52.30 % -74.55 % -12.00 % -62.70 % -52.79 % 7.50 % -16.54 % -58.29 % -78.63 %
3Y -99.50 % -89.16 % -67.65 % -73.48 % 40.53 % 321.15 % 141.76 % -74.93 % -85.56 %
5Y -99.23 % -97.74 % -86.12 % -90.59 % -49.92 % 101.45 % 164.25 % -81.98 % -93.14 %
10Y -99.77 % -97.47 % -86.12 % -91.39 % -49.92 % 97.81 % 80.80 % -70.65 % -94.62 %
From the beginning -99.77 % -97.47 % -86.12 % -91.39 % -49.92 % 97.81 % 80.80 % -70.65 % -94.62 %

Dividend